(VIANEWS) – ANI Pharmaceuticals (ANIP), United Therapeutics Corporation (UTHR), STAAR Surgical Company (STAA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ANI Pharmaceuticals (ANIP)
39.5% sales growth and 3.38% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $0.54.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 101.19. Meaning, the purchaser of the share is investing $101.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.38%.
Moving Average
ANI Pharmaceuticals’s value is above its 50-day moving average of $53.28 and above its 200-day moving average of $53.15.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ANI Pharmaceuticals’s EBITDA is 40.06.
Sales Growth
ANI Pharmaceuticals’s sales growth is 28.9% for the current quarter and 39.5% for the next.
Yearly Top and Bottom Value
ANI Pharmaceuticals’s stock is valued at $54.64 at 19:22 EST, way under its 52-week high of $65.89 and way above its 52-week low of $36.54.
2. United Therapeutics Corporation (UTHR)
18.7% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.13.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 11.77. Meaning, the purchaser of the share is investing $11.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
United Therapeutics Corporation’s EBITDA is 22.91.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 2.2B for the twelve trailing months.
3. STAAR Surgical Company (STAA)
13.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 73.34. Meaning, the purchaser of the share is investing $73.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 41.7% and a drop 11.1% for the next.
4. American Express (AXP)
9.5% sales growth and 31.77% return on equity
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products and services also comprise merchant acquisition and processing, servicing and settlement, point-of-sale marketing, and information products and services for merchants; and fraud prevention services, as well as the design and operation of customer loyalty programs. It sells its products and services to consumers, small businesses, mid-sized companies, and large corporations through mobile and online applications, third-party vendors and business partners, direct mail, telephone, in-house sales teams, and direct response advertising. American Express Company was founded in 1850 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, American Express has a trailing twelve months EPS of $11.22.
PE Ratio
American Express has a trailing twelve months price to earnings ratio of 18.39. Meaning, the purchaser of the share is investing $18.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.77%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 55.59B for the twelve trailing months.
